[ CAS No. 635712-49-1 ]

Name: 635712-49-1|5-Bromo-7-ethyl-1H-indazole|95%
Brand: Ambeed
SKU: A135010
Price: 41.0 USD
Availability: InStock
Rating: 99 (40 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 635712-49-1

Structure of 635712-49-1 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 88K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 635712-49-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 635712-49-1 ]

SDS

Alternatived Products of [ 635712-49-1 ]

Product Details of [ 635712-49-1 ]

CAS No. :	635712-49-1	MDL No. :	MFCD11044594
Formula :	C₉H₉BrN₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	N/A
M.W :	225.09 g/mol	Pubchem ID :	21102195
Synonyms :

Calculated chemistry of of [ 635712-49-1 ]

Physicochemical Properties

Num. heavy atoms :	12
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.22
Num. rotatable bonds :	1
Num. H-bond acceptors :	1.0
Num. H-bond donors :	1.0
Molar Refractivity :	53.57
TPSA :	28.68 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.51 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.16
Log Po/w (XLOGP3) :	3.04
Log Po/w (WLOGP) :	2.89
Log Po/w (MLOGP) :	2.49
Log Po/w (SILICOS-IT) :	3.46
Consensus Log Po/w :	2.81

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.64
Solubility :	0.0516 mg/ml ; 0.000229 mol/l
Class :	Soluble
Log S (Ali) :	-3.31
Solubility :	0.111 mg/ml ; 0.000492 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.56
Solubility :	0.00617 mg/ml ; 0.0000274 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.77

Safety of [ 635712-49-1 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 635712-49-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 635712-49-1 ]
Downstream synthetic route of [ 635712-49-1 ]

[ 635712-49-1 ] Synthesis Path-Upstream 1~5

1
[ 70598-49-1 ]
[ 635712-49-1 ]

Yield	Reaction Conditions	Operation in experiment
79.2%	Stage #1: With potassium acetate; acetic anhydride In chloroform at 0 - 20℃; for 1 h; Inert atmosphere Stage #2: With tert.-butylnitrite In chloroform at 60℃;	To a solution of 47-S2 (6 g, 28.2 mmol)and KOAc (3.3 g 33.8 mmol) in CHC13 (60 mL) was added dropwise acetic anhydride (8.6 g, 86.4mmol) at 0 DC under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 CC and tert-butyl nitrite (5.8 g, 56.4 mmol) was added. The resulting mixture was stirred at 60 °C overnight. The mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4and concentrated. The remaining residue was dissolved in MeOH and 6 N aqueous HC1 (20 mL) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated to afford 47-S3 (5.0 g, 79.2percent yield) as a light a yellow solid. LC/MS (ESI) m/z: 225 (M+H) .

Reference： [1] Patent: WO2018/160889, 2018, A1, . Location in patent: Page/Page column 511; 512

2
[ 943145-76-4 ]
[ 635712-49-1 ]

Yield	Reaction Conditions	Operation in experiment
85%	Stage #1: With potassium <i>tert</i>-butylate In dimethyl sulfoxide for 1 h; Nitrogen atmosphere Stage #2: With hydrogenchloride In water; dimethyl sulfoxide	To a stirred solution of potassium t-butoxide (33.6 g, 10 equiv. ) in DMSO (200 mL) was added a solution of 4-bromo-2-ethyl-6-methylphenyldiazo-t-butyl sulfide (9. [4] g, 30 mmol) in DMSO (100 mL) via cannula. The mixture was stirred vigorously for 1 h. The reaction mixture was then carefully poured into a mixture of crushed ice (500 mL), concentrated hydrochloric acid (25 mL), and water (100 mL). The resulting precipitate was filtered, washed with water, dissolved in methanol, and concentrated to give 5.7 g (85percent) as a tan [SOLID. 1H-NMR (CDC13,] 500 MHz) [8 1.] 39 (t, J=7.6, 3H), 2.92 (q, [J=7.] 6,2H), 7.30 (s, 1H), 7.75 (s, 1H), 8.04 (s, 1H). Mass spec.: 225.00 [(MH) +.]

Reference： [1] Patent: WO2003/104236, 2003, A1, . Location in patent: Page 127

3
[ 70598-49-1 ]
[ 635712-49-1 ]
[ 1031417-71-6 ]

Yield	Reaction Conditions	Operation in experiment
33%	Stage #1: With sodium nitrite In acetic acid at 20℃; Stage #2: With sodium nitrite In water; acetic acid	To a solution of 2-ethyl-6-methylaniline (2.03 g, 15 mmol) in DMF (50 mL) at 0 C was added N-bromosuccinimide (2.66 g, 14.9 mmol). The mixture was stirred at room temperature for 10 minutes before addition to saturated aqueous NaCI. The mixture was extracted with EtOAc, the organic phase was washed with sat aqueous NaCI (2x), concentrated and the crude material was purified by Biotage chromatography (4OM, 15percent EtOAc/heptane) to provide 4-bromo-2-ethyl-6-methylbenzenamine as a red brown liquid (3.21 g, 100percent).A solution of 4-bromo-2-ethyl-6-methylbenzenamine (3.21 g, 15 mmol) in acetic acid (50 mL) was stirred for 3 hours before addition of a 2 M solution of sodium nitrite (11 mL, 22.5 mmol). The resulting mixture was stirred overnight at room temperature. The solution was concentrated and the solid was dissolved in EtOAc and washed with saturated aqueous NaCI (3x). The organic extract was dried over Na2SO4, filtered and concentrated, the crude material was purified by Biotage chromatography (4OM, 15- 30percent EtOAc/heptane) to provide 5-bromo-7-ethyl-1H-indazole (1.11 g, 33percent) and 5-bromo-3,7-dimethyl- 1H-indazole (0.84 g, 25percent).To a solution of 5-bromo-7-ethyl-1H-indazole (225 mg, 1.00 mmol) in dioxane (1.5 mL), hexacarbonylmolybdenum (132 mg, 0.50 mmol), Herrmann's catalyst (trans-Bis(acetato)bis[o-(di-o- tolylphosphino)benzyl]dipalladium) (46.9 mg, 0.05 mmol) and a solution of sodium carbonate (318 mg, 3.00 mmol) in water (2 mL). The suspension was sealed and irradiated in a microwave at 165 ⁰C for 15 minutes (high absorption setting). The vial was vented , filtered through diatomaceous earth, washed with EtOAc and concentrated to provide the title compound (140 mg, 74percent).

Reference： [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[2] Patent: WO2008/65508, 2008, A1, . Location in patent: Page/Page column 31

4
[ 24549-06-2 ]
[ 635712-49-1 ]

Reference： [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[2] Patent: WO2018/160889, 2018, A1,
[3] Patent: WO2008/65508, 2008, A1,

5
[ 70598-49-1 ]
[ 635712-49-1 ]
[ 1031417-71-6 ]

Yield	Reaction Conditions	Operation in experiment
33%	Stage #1: With sodium nitrite In acetic acid at 20℃; Stage #2: With sodium nitrite In water; acetic acid	To a solution of 2-ethyl-6-methylaniline (2.03 g, 15 mmol) in DMF (50 mL) at 0 C was added N-bromosuccinimide (2.66 g, 14.9 mmol). The mixture was stirred at room temperature for 10 minutes before addition to saturated aqueous NaCI. The mixture was extracted with EtOAc, the organic phase was washed with sat aqueous NaCI (2x), concentrated and the crude material was purified by Biotage chromatography (4OM, 15percent EtOAc/heptane) to provide 4-bromo-2-ethyl-6-methylbenzenamine as a red brown liquid (3.21 g, 100percent).A solution of 4-bromo-2-ethyl-6-methylbenzenamine (3.21 g, 15 mmol) in acetic acid (50 mL) was stirred for 3 hours before addition of a 2 M solution of sodium nitrite (11 mL, 22.5 mmol). The resulting mixture was stirred overnight at room temperature. The solution was concentrated and the solid was dissolved in EtOAc and washed with saturated aqueous NaCI (3x). The organic extract was dried over Na2SO4, filtered and concentrated, the crude material was purified by Biotage chromatography (4OM, 15- 30percent EtOAc/heptane) to provide 5-bromo-7-ethyl-1H-indazole (1.11 g, 33percent) and 5-bromo-3,7-dimethyl- 1H-indazole (0.84 g, 25percent).To a solution of 5-bromo-7-ethyl-1H-indazole (225 mg, 1.00 mmol) in dioxane (1.5 mL), hexacarbonylmolybdenum (132 mg, 0.50 mmol), Herrmann's catalyst (trans-Bis(acetato)bis[o-(di-o- tolylphosphino)benzyl]dipalladium) (46.9 mg, 0.05 mmol) and a solution of sodium carbonate (318 mg, 3.00 mmol) in water (2 mL). The suspension was sealed and irradiated in a microwave at 165 ⁰C for 15 minutes (high absorption setting). The vial was vented , filtered through diatomaceous earth, washed with EtOAc and concentrated to provide the title compound (140 mg, 74percent).

Reference： [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 2, p. 935 - 942
[2] Patent: WO2008/65508, 2008, A1, . Location in patent: Page/Page column 31

[ 635712-49-1 ] Synthesis Path-Downstream 1~20

1
[ 943145-76-4 ]
[ 635712-49-1 ]

Yield	Reaction Conditions	Operation in experiment
85%		To a stirred solution of potassium t-butoxide (33.6 g, 10 equiv. ) in DMSO (200 mL) was added a solution of 4-bromo-2-ethyl-6-methylphenyldiazo-t-butyl sulfide (9. [4] g, 30 mmol) in DMSO (100 mL) via cannula. The mixture was stirred vigorously for 1 h. The reaction mixture was then carefully poured into a mixture of crushed ice (500 mL), concentrated hydrochloric acid (25 mL), and water (100 mL). The resulting precipitate was filtered, washed with water, dissolved in methanol, and concentrated to give 5.7 g (85%) as a tan [SOLID. 1H-NMR (CDC13,] 500 MHz) [8 1.] 39 (t, J=7.6, 3H), 2.92 (q, [J=7.] 6,2H), 7.30 (s, 1H), 7.75 (s, 1H), 8.04 (s, 1H). Mass spec.: 225.00 [(MH) +.]

Reference： [1]Patent: WO2003/104236,2003,A1 .Location in patent: Page 127

Yield	Reaction Conditions	Operation in experiment
		5-Bromo-7-ethyl-1H-indazole To a stirred solution of potassium t-butoxide (33.6 g, 10 equiv.) in DMSO (200 mL) was added a solution of 4-bromo-2-ethyl-6-methylphenyldiazo-t-butyl sulfide (9.4 g, 30 mmol) in DMSO (100 mL) via cannula. The mixture was stirred vigorously for 1 h. The reaction mixture was then carefully poured into a mixture of crushed ice (500 mL), concentrated hydrochloric acid (25 mL), and water (100 mL). The resulting precipitate was filtered, washed with water, dissolved in methanol, and concentrated to give 5.7 g (85%) as a tan solid. 1H-NMR (CDCl3, 500 MHz) delta 1.39 (t, J=7.6, 3H), 2.92 (q, J=7.6, 2H), 7.30 (s, 1H), 7.75 (s, 1H), 8.04 (s, 1H). Mass spec.: 225.00 (MH)+.

3
[ 635712-49-1 ]
[ 635712-50-4 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium hydrogen sulphate; tert.-butyl lithium; In tetrahydrofuran; N-methyl-acetamide; water; pentane;	7-Ethyl-1H-indazole-5-carbaldehyde 5-Bromo-7-ethyl-1H-indazole (2.0 g, 8.9 mmol) and sodium hydride (226 mg, 1.1 equiv.) were weighed into a flame-dried round-bottom flask containing a magnetic stir bar. Under a nitrogen atmosphere at room temperature, dry tetrahydrofuran (60 mL) was added. The mixture was stirred at room temperature for 15 min. The stirred mixture was cooled to -78 C. and a solution of tert-butyllithium in pentane (1.7 M, 10.5 mL, 2.0 equiv.) was added over several minutes. After 15 min at -78 C., the reaction was gradually warmed to to -50 C., and recooled to -78 C. Dimethylformamide (2.8 mL) was slowly added and the mixture allowed to warm to -50 C. The solution was quickly transferred to a stirred solution of water 300 mL and 1 M potassium hydrogen sulfate (25 mL). The resulting suspension was extracted with diethyl ether, washed with water, then brine, dried over magnesium sulfate, and concentrated. Column chromatography gave 160 mg (10%) as a white solid. 1H-NMR (CD3OD, 500 MHz) delta 1.38 (t, J=7.6, 3H), 2.98 (q, J=7.6, 2H), 7.71 (s, 1H), 8.22 (s, 1H), 8.24 (s, 1H), 9.96 (s, 1H). Mass spec.: 175.08 (MH)+.

Reference： [1]Patent: US2004/204397,2004,A1

4
[ 70598-49-1 ]
[ 635712-49-1 ]
[ 1031417-71-6 ]

Yield	Reaction Conditions	Operation in experiment
33%; 25%		To a solution of 2-ethyl-6-methylaniline (2.03 g, 15 mmol) in DMF (50 mL) at 0 C was added N-bromosuccinimide (2.66 g, 14.9 mmol). The mixture was stirred at room temperature for 10 minutes before addition to saturated aqueous NaCI. The mixture was extracted with EtOAc, the organic phase was washed with sat aqueous NaCI (2x), concentrated and the crude material was purified by Biotage chromatography (4OM, 15% EtOAc/heptane) to provide 4-bromo-2-ethyl-6-methylbenzenamine as a red brown liquid (3.21 g, 100%).A solution of 4-bromo-2-ethyl-6-methylbenzenamine (3.21 g, 15 mmol) in acetic acid (50 mL) was stirred for 3 hours before addition of a 2 M solution of sodium nitrite (11 mL, 22.5 mmol). The resulting mixture was stirred overnight at room temperature. The solution was concentrated and the solid was dissolved in EtOAc and washed with saturated aqueous NaCI (3x). The organic extract was dried over Na2SO4, filtered and concentrated, the crude material was purified by Biotage chromatography (4OM, 15- 30% EtOAc/heptane) to provide 5-bromo-7-ethyl-1H-indazole (1.11 g, 33%) and 5-bromo-3,7-dimethyl- 1H-indazole (0.84 g, 25%).To a solution of 5-bromo-7-ethyl-1H-indazole (225 mg, 1.00 mmol) in dioxane (1.5 mL), hexacarbonylmolybdenum (132 mg, 0.50 mmol), Herrmann's catalyst (trans-Bis(acetato)bis[o-(di-o- tolylphosphino)benzyl]dipalladium) (46.9 mg, 0.05 mmol) and a solution of sodium carbonate (318 mg, 3.00 mmol) in water (2 mL). The suspension was sealed and irradiated in a microwave at 165 0C for 15 minutes (high absorption setting). The vial was vented , filtered through diatomaceous earth, washed with EtOAc and concentrated to provide the title compound (140 mg, 74%).

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 935 - 942
[2]Patent: WO2008/65508,2008,A1 .Location in patent: Page/Page column 31

5
[ 635712-49-1 ]
[ 13939-06-5 ]
[ 1031417-67-0 ]

Yield	Reaction Conditions	Operation in experiment
74%	With sodium carbonate;trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium; In 1,4-dioxane; water; at 165℃; for 0.25h;	To a solution of 2-ethyl-6-methylaniline (2.03 g, 15 mmol) in DMF (50 mL) at 0 C was added N-bromosuccinimide (2.66 g, 14.9 mmol). The mixture was stirred at room temperature for 10 minutes before addition to saturated aqueous NaCI. The mixture was extracted with EtOAc, the organic phase was washed with sat aqueous NaCI (2x), concentrated and the crude material was purified by Biotage chromatography (4OM, 15% EtOAc/heptane) to provide 4-bromo-2-ethyl-6-methylbenzenamine as a red brown liquid (3.21 g, 100%).A solution of 4-bromo-2-ethyl-6-methylbenzenamine (3.21 g, 15 mmol) in acetic acid (50 mL) was stirred for 3 hours before addition of a 2 M solution of sodium nitrite (11 mL, 22.5 mmol). The resulting mixture was stirred overnight at room temperature. The solution was concentrated and the solid was dissolved in EtOAc and washed with saturated aqueous NaCI (3x). The organic extract was dried over Na2SO4, filtered and concentrated, the crude material was purified by Biotage chromatography (4OM, 15- 30% EtOAc/heptane) to provide <strong>[635712-49-1]5-bromo-7-ethyl-1H-indazole</strong> (1.11 g, 33%) and 5-bromo-3,7-dimethyl- 1H-indazole (0.84 g, 25%).To a solution of <strong>[635712-49-1]5-bromo-7-ethyl-1H-indazole</strong> (225 mg, 1.00 mmol) in dioxane (1.5 mL), hexacarbonylmolybdenum (132 mg, 0.50 mmol), Herrmann's catalyst (trans-Bis(acetato)bis[o-(di-o- tolylphosphino)benzyl]dipalladium) (46.9 mg, 0.05 mmol) and a solution of sodium carbonate (318 mg, 3.00 mmol) in water (2 mL). The suspension was sealed and irradiated in a microwave at 165 0C for 15 minutes (high absorption setting). The vial was vented , filtered through diatomaceous earth, washed with EtOAc and concentrated to provide the title compound (140 mg, 74%).

Reference： [1]Patent: WO2008/65508,2008,A1 .Location in patent: Page/Page column 31

6
[ 635712-49-1 ]
[ 68-12-2 ]
[ 635712-50-4 ]

Yield	Reaction Conditions	Operation in experiment
10%		[5-BROMO-7-ETHYL-LH-INDAZOLE] (2.0 g, 8.9 mmol) and sodium hydride (226 mg, 1.1 equiv. ) were weighed into a flame-dried round-bottom flask containing a magnetic stir bar. Under a nitrogen atmosphere at room temperature, dry tetrahydrofuran (60 mL) was added. The mixture was stirred at room temperature for 15 min. The stirred mixture was cooled to-78C and a solution of tert-butyllithium in pentane (1.7 M, 10.5 mL, 2.0 equiv. ) was added over several minutes. After 15 min [AT-78C,] the reaction was gradually warmed to [TO-50C,] and recooled [TO-78C.] [DIMETHYLFORMAMIDE] (2. [8] mL) was slowly added and the mixture allowed to warm to [- 50C.] The solution was quickly transferred to a stirred solution of water 300 [ML] and 1 M potassium hydrogen sulfate (25 mL). The resulting suspension was extracted with diethyl ether, washed with water, then brine, dried over magnesium sulfate, and concentrated. Column chromatography gave 160 mg (10%) as a white [SOLID. IH-NMR (CD30D,] 500 MHz) [8] 1.38 (t, J=7. 6,3H), 2.98 (q, J=7. 6,2H), 7.71 (s, [L. H),] 8.22 (s, 1H), 8.24 (s, 1H), 9.96 (s, 1H). Mass spec.: 175.08 [(MH)'.]

Reference： [1]Patent: WO2003/104236,2003,A1 .Location in patent: Page 127-128
[2]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1870 - 1873

7
[ 635712-49-1 ]
[ 1197939-08-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 935 - 942

8
[ 635712-49-1 ]
[ 497-19-8 ]
[ 1031417-67-0 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 935 - 942

9
[ 24549-06-2 ]
[ 635712-49-1 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 935 - 942
[2]Patent: WO2018/160889,2018,A1
[3]Patent: WO2008/65508,2008,A1

10
[ 67-56-1 ]
[ 635712-49-1 ]
[ 201230-82-2 ]
[ 1197944-03-8 ]

Reference： [1]Synthetic Communications,2012,vol. 42,p. 1914 - 1921

11
C₁₃H₁₉BrN₂ [ No CAS ]
[ 635712-49-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1870 - 1873

12
[ 635712-49-1 ]
[ 635712-51-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1870 - 1873

13
[ 635712-49-1 ]
[ 635712-52-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1870 - 1873

14
[ 70598-49-1 ]
[ 635712-49-1 ]

Yield	Reaction Conditions	Operation in experiment
79.2%		To a solution of 47-S2 (6 g, 28.2 mmol)and KOAc (3.3 g 33.8 mmol) in CHC13 (60 mL) was added dropwise acetic anhydride (8.6 g, 86.4mmol) at 0 DC under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 CC and tert-butyl nitrite (5.8 g, 56.4 mmol) was added. The resulting mixture was stirred at 60 C overnight. The mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4and concentrated. The remaining residue was dissolved in MeOH and 6 N aqueous HC1 (20 mL) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated to afford 47-S3 (5.0 g, 79.2% yield) as a light a yellow solid. LC/MS (ESI) m/z: 225 (M+H) .

Reference： [1]Patent: WO2018/160889,2018,A1 .Location in patent: Page/Page column 511; 512

15
[ 635712-49-1 ]
5-bromo-7-ethyl-3-iodo-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93.2%	With iodine; potassium hydroxide; In N,N-dimethyl-formamide; at 0℃; for 0.5h;	To a solution of 47-S3 (4.5 g,20.lmmol) in DMF (50 mL) were added KOH (2.53 g, 45.23 mmol) and iodine (7.65 g, 30.15 mmol) at 0 C. The reaction mixture was stirred at 0 C for 30 minutes. The reaction mixture was quenched by addition of saturated aqueous Na2S2O3 solution (15 mL). The mixture was diluted with DCM and washed with 10% aqueous LiC1 solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness to afford 47-S4 (6.56 g, 93.2% yield) as awhite solid. LC/MS (ESI) m/z: 351 (M+H)t

Reference： [1]Patent: WO2018/160889,2018,A1 .Location in patent: Page/Page column 511; 512; 513

16
[ 635712-49-1 ]
tert-butyl 2-(5-bromo-7-ethyl-3-iodo-1H-indazol-1-yl)acetate [ No CAS ]